Earnings Call · Q4 FY2024·2025-02-28

Q4 24EPS -100.00%*·Rev n/aQ3 24EPS +22.94%·Rev n/aQ2 24EPS +7.37%·Rev n/aQ1 24EPS +21.00%·Rev n/a⚠ consensus missing

ANI PHARMACEUTICALS INC ANIP

Lisa Wilson — Investor Relations

Nikhil Lalwani — President and Chief Executive Officer

Christopher Mutz — Senior Vice-President and Head of Rare Disease

Stephen Carey — Chief Financial Officer

+2.1%1d on move date+1.7% vs SPY3d+3.3%5d+2.2%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ANIP calls or request research access.

More ANIP calls Browse calls Request research access